Imperva (NASDAQ:IMPV) was upgraded by investment analysts at ValuEngine from a “hold” rating to a “buy” rating in a research report issued on Thursday.
Several other research firms have also recently issued reports on IMPV. Oppenheimer cut shares of Imperva from an “outperform” rating to a “market perform” rating and set a $70.00 target price on the stock. in a research note on Friday, July 27th. BidaskClub cut shares of Imperva from a “strong-buy” rating to a “buy” rating in a research note on Saturday, June 23rd. Stephens upped their target price on shares of Imperva from $61.00 to $67.00 and gave the company an “overweight” rating in a research note on Thursday, June 14th. JPMorgan Chase & Co. upped their target price on shares of Imperva from $45.00 to $48.00 and gave the company an “underweight” rating in a research note on Friday, July 27th. Finally, DA Davidson cut shares of Imperva from a “buy” rating to a “neutral” rating and lowered their target price for the company from $56.00 to $46.00 in a research note on Friday, July 27th. Eleven research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average price target of $56.37.
IMPV opened at $55.36 on Thursday. The stock has a market cap of $1.61 billion, a price-to-earnings ratio of -197.71 and a beta of 1.72. Imperva has a 52-week low of $37.17 and a 52-week high of $57.65.
Imperva (NASDAQ:IMPV) last posted its earnings results on Thursday, July 26th. The software maker reported ($0.26) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.33) by $0.07. The business had revenue of $84.80 million for the quarter, compared to analysts’ expectations of $87.22 million. Imperva had a negative net margin of 8.59% and a negative return on equity of 6.92%. The business’s revenue for the quarter was up 13.9% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.24 EPS. On average, equities research analysts forecast that Imperva will post -1.15 earnings per share for the current fiscal year.
Several large investors have recently modified their holdings of the company. Bank of Montreal Can lifted its stake in shares of Imperva by 21.1% in the 3rd quarter. Bank of Montreal Can now owns 41,778 shares of the software maker’s stock worth $1,940,000 after purchasing an additional 7,268 shares during the period. United Services Automobile Association lifted its stake in shares of Imperva by 5.0% in the 2nd quarter. United Services Automobile Association now owns 49,973 shares of the software maker’s stock worth $2,411,000 after purchasing an additional 2,400 shares during the period. Northern Trust Corp lifted its stake in shares of Imperva by 4.6% in the 2nd quarter. Northern Trust Corp now owns 433,433 shares of the software maker’s stock worth $20,913,000 after purchasing an additional 19,224 shares during the period. Bank of New York Mellon Corp lifted its stake in shares of Imperva by 7.0% in the 2nd quarter. Bank of New York Mellon Corp now owns 159,349 shares of the software maker’s stock worth $7,689,000 after purchasing an additional 10,461 shares during the period. Finally, Bank of Nova Scotia bought a new position in shares of Imperva in the 2nd quarter worth approximately $3,329,000. Hedge funds and other institutional investors own 99.99% of the company’s stock.
Imperva, Inc engages in the development, market, sale, and support of cyber security solutions that protect business critical data and applications in the cloud or on premises worldwide. The company's SecureSphere product line provides database, file, and Web application security in various data centers, including on-premises data centers, as well as in private, public, and hybrid cloud computing environments.
Featured Story: What is a conference call?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Imperva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Imperva and related companies with MarketBeat.com's FREE daily email newsletter.